US › Healthcare

TuHURA Biosciences Inc (HURA)

US · Healthcare · Biotechnology

$2.09-2.34%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-7.5M
Profit YoY
-13.1%
EPS
$-0.13
EPS estimate
$-0.11

EPS came in at -0.13 against a street estimate of -0.11 — a miss of 18.2%.

Key statistics

Market cap
$136.3M
Forward P/E
0.0
P/B
6.03
Book value
$0.36
EPS (TTM)
$-0.61
52-week high
$3.90
52-week low
$0.41
50-day MA
$2.28
200-day MA
$1.84

Analyst view

Analysts rate TuHURA Biosciences Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.04.

Shareholding

Insiders
34.65%
Institutions
14.88%

Largest institutional holders

FundStake
BlackRock Inc3.85%
Vanguard Group Inc3.64%
Vanguard Capital Management, LLC3.26%
Geode Capital Management, LLC1.55%
AQR Capital Management LLC0.95%
State Street Corp0.81%
Northern Trust Corp0.47%
Vanguard Fiduciary Trust Co0.45%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for TuHURA Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.